People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viela Bio, Inc. | — | Biotechnology | Series D+ | $357.3M | $3.1B | 2018 |
| ArriVent Biopharma, Inc. | — | Biotechnology | Series D+ | $260.0M | $2.0B | 2021 |
Zhengbin (Bing) Yao at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zhengbin (Bing) Yao on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| James Healy | 1 | 8 |
| Tyrell Rivers | 1 | 6 |
| Jason Zhang | 1 | 3 |
| Bahija Jallal | 1 | 3 |
| Wenkai Xiang | 1 | 2 |
| Edward Hu | 1 | 2 |
| Yanling (Bing) Cao | 1 | 1 |
| Xiaomeng (Bing) Tong | 1 | 1 |
| Matthew (Bing) Pietras | 1 | 1 |
| Wenkai (Bing) Xiang | 1 | 1 |
| Bahija (Bing) Jallal | 1 | 1 |
| Ting (Bing) Jia | 1 | 1 |
| Stuart Lutzker | 1 | 1 |
| Cong Xu | 1 | 1 |
| Xiaomeng Tong | 1 | 1 |
| Andreas Wicki | 1 | 1 |
| Yanling Cao | 1 | 1 |
| Pascal Soriot | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.